11:13 AM EDT, 06/26/2024 (MT Newswires) -- Novo Nordisk A/S ( NVO ) said Wednesday it will recognize an impairment loss of around 5.7 billion Danish Krone ($816.2 million) in Q2 after its Clarion-CKD phase 3 trial failed to meet its primary endpoint.
Price: 144.19, Change: -2.72, Percent Change: -1.85